Clinical Trial Update: Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of suicide gene–modified donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hematological Malignancy | Phase 1, Phase 2 | Status: COMPLETED